Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C131491> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- NCIT_C131491 IAO_0000115 "A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle formulation selectively targets and preferentially accumulates in tumor vessels and cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine (PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation within the internal membrane. SapC becomes active in the acidic tumor microenvironment and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide to ceramide, respectively. This elevates intracellular ceramide levels, activates caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition of tumor cell growth. SapC plays key roles in lipid transport and organization of biological membranes and has strong lipid membrane binding activity." @default.
- NCIT_C131491 NCIT_A32 NCIT_C1909 @default.
- NCIT_C131491 NCIT_NHC0 "C131491" @default.
- NCIT_C131491 NCIT_P106 "Organic Chemical" @default.
- NCIT_C131491 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C131491 NCIT_P107 "BXQ-350 Nanovesicle Formulation" @default.
- NCIT_C131491 NCIT_P108 "BXQ-350 Nanovesicle Formulation" @default.
- NCIT_C131491 NCIT_P208 "CL514261" @default.
- NCIT_C131491 NCIT_P319 "2N62LTC861" @default.
- NCIT_C131491 NCIT_P322 "CTRP" @default.
- NCIT_C131491 NCIT_P322 "FDA" @default.
- NCIT_C131491 NCIT_P322 "GDC" @default.
- NCIT_C131491 NCIT_P329 "785725" @default.
- NCIT_C131491 NCIT_P330 "785725" @default.
- NCIT_C131491 NCIT_P375 "BXQ-350 Nanovesicle Formulation" @default.
- NCIT_C131491 NCIT_P399 "785725" @default.
- NCIT_C131491 normalizedInformationContent "100" @default.
- NCIT_C131491 referenceCount "1" @default.
- NCIT_C131491 hasExactSynonym "BXQ-350 Nanovesicle Formulation" @default.
- NCIT_C131491 hasExactSynonym "BXQ-350" @default.
- NCIT_C131491 hasExactSynonym "SAPOSIN C (NON-GLYCOSYLATED)" @default.
- NCIT_C131491 hasExactSynonym "SapC-DOPS Nanovesicles" @default.
- NCIT_C131491 hasExactSynonym "Saposin C-Dioleoylphosphatidylserine Complexes" @default.
- NCIT_C131491 hasExactSynonym "Saposin C-Dioleoylphosphatidylserine Nanovesicles" @default.
- NCIT_C131491 inSubset NCIT_C116977 @default.
- NCIT_C131491 inSubset NCIT_C116978 @default.
- NCIT_C131491 inSubset NCIT_C128784 @default.
- NCIT_C131491 inSubset NCIT_C157711 @default.
- NCIT_C131491 inSubset NCIT_C157712 @default.
- NCIT_C131491 inSubset NCIT_C176424 @default.
- NCIT_C131491 inSubset NCIT_C177537 @default.
- NCIT_C131491 inSubset NCIT_C63923 @default.
- NCIT_C131491 type Class @default.
- NCIT_C131491 isDefinedBy ncit.owl @default.
- NCIT_C131491 label "BXQ-350 Nanovesicle Formulation" @default.
- NCIT_C131491 subClassOf NCIT_C129839 @default.
- NCIT_C131491 subClassOf NCIT_C131491 @default.
- NCIT_C131491 subClassOf NCIT_C1908 @default.
- NCIT_C131491 subClassOf NCIT_C1909 @default.
- NCIT_C131491 subClassOf NCIT_C274 @default.